Slide 1: Investor Presentation March 2016
S ChromaDex Investor Presentation March 2016
Slide 2: Disclaimers
Disclaimers Safe Harbor FDA Disclaimer Sc ChromaDex
Slide 3: Market Statistics
Market Stati ics COXC(CTCAX) Shares Outstane $1.50, Market gt 109.5 Key cen a ot 3707201) siete Statistics ses ara op 175 128000 Employes On = ‘Shareholders? Shares | a guthrie eens leaauns See ee ee sonia ChromaDex (9) OPKO DSM
Slide 4: ChromaDex Overview
ChromaDex Overview * ChromaDex is an innovator of proprietary health, wales and paisa! ingredient: le at kin care rts nutrition, result of our relationships with leading universities and resea inailntlonss we to search are abl discover and license early stage, IP-backed ingredient technologies. NI A
Slide 5: Dramatic Growth in Ingredient Sales
Dramatic Growth in Ingredient Sales cz aa qazs aos 82015 ingredient Sales in ions
Slide 6: Lead Ingredient — NIAGEN
Lead Ingredient — N IAGEN ChromaDex launched NIAGEN ® in taney 2013. O° ° ° cr ~ = ‘OH A wosinaiso SW Hoes N Nicotinic Acid (Niacin) Nicotinamide Riboside ChromaDex. b (NIAGEN) OH OH A
Slide 7: NIAGEN - The Most Effective NAD+ Precursor
NIAGEN.- The Most Effective NAD+ Precursor applications". NAD+ and mitochondrial function decline with aging, Many nutrionally addressable health problems includ it ‘and neurological conditions, metabolic disorders HAL dioketes Gm seeaty mia fi bility. Recent human data confirms that NIAGEN® boosts
Slide 8: Why NAD+ is Important
Why NAD+ is Important is a coenzyme found in all living cells... Cellular NAD* concentrations change during aging, and modulation of NAD* NAD*) health span and life span.” Scrromapex bh
Slide 9: NAD+ and Mitochondrial Function Declines with Aging
NAD+ and Mitochondrial Function Declines with Aging i g Human Data - NAD+ levels decrease dramatically with age 5 Mouse Data — Energy, rier fee wie nondrial 2 DNA population and integrity 2 -° ge g i Ee 0 © chromadex
Slide 10: NAD+ Reverses Mitochondrial Dysfunction
NAD+ Reverses Mitochondrial Dysfunction NAD+ in tissues with high mitochondrial function and mitochondria content. mitochondrial biogenesis. bad Mowe Data Mouse Data 2 amor 5 8,000 : j ab il : 2 000 eed ree 4 ! A iin hn i a 22 os be 2 3 200 ° i ‘Ta| 2 fin Muscle oa Lf Sc ChromaDex é soe cee eee
Slide 11: NR and Mitochondrial Function
NR and Mitochondrial Function S ChromaDex
Slide 12: The Science of Living Longer
The Science of Living Longer Healthy Aging & Healthspan dementia, and chronic diseases.
Slide 13: Age: A Major Underlying Factor in Disease
Age: A Major Underlying Factor in Disease Yet research hos “Aging” is not a disease, age underlays the progression and costs of most major diseases: Sc ChromaDex
Slide 14: Pharmaceutical Interest in Aging as a Disease
Pharmaceutical Interest in Aging as a Disease Calico UNITY Biotechnology CEO of Genentech recently es the space with additional backing from AbbVi *Calico's area of focus is aging and age-related diseases, such as neurodegeneration and cancer. NAD+ levels. ChromaDex b “Medicines are designed to leng
Slide 15: Results of First Study
Results of First Study a + 2015, i Second Study eight consecutive weeks. the body apse "Demonstrating that NR is an effective precursor fo increase NAD+ in humans has significant positiv the effects of aging, obesity and disease.” rd, ‘ond may be a cornerstone fo developing solutions fo delay or rev
Slide 16: Additional Clinical Studies
Additional Clinical Studies . University of Copenhagen Dr: Jonas Tresbaly, a Researcher Wih The Novo Nordisk Foundation Contr fr Bosic Metabolic Research (University of Copenhagen, Denmark) is, in Sellaboratiay with researchers at Aarhus University, imestaang heim metabolic and insulin sensitizing e
Slide 17: NAD+ Deficiencies
NAD+ Deficiencies funeti disease, liver orphan diseases including: * Cockayne Syndrome — N * Mitochondrial iencly- vie UCL UK * Progeria — Buck Institute ChromaDex
Slide 18: Pharmaceutical Opportunities
Pharmaceutical Opportunities NIH Study ; ; : ; @ Simatic related neurodegenerative conditions. sed exclusive rights from Darfmouth for several patents related fo the lude protection for human In June 2014, ChromaDex licens pharmaceutical use of Teoma Fe (NR). The licensed patents inc! therapeutic us
Slide 19: Research Collaborations with NIAGEN
Research Collaborations with NIAGEN B aheanscikss HE scyooe Morea oO UCTRvINE Wir ey UCDAVIS $8 Dartmouth ChromaDex MAYO. CLINIC f “Tue Univers ‘oriowa UNIVERSITY of WASHINGTON = Washington Unvestyinseous Mics Cockayne pathy Syndrome is Disease Browning of Adipocytes
Slide 20: Regulatory Update
Regulatory Update New Dietary Ingredient (NDI) notifications in FY 2014 Generally Recognized as Safe (GRAS) NIAGEN can be used in food & beverage products European Food saety Authority (EFSA) cropap, & © # 0
Slide 21: NIAGEN as a Platform Ingredient
NIAGEN. as a Platform Ingredient aS Scrromapex bh
Slide 22: NIAGEN Commercial Deployment
NIAGEN. i i of Di pp rod
Slide 23: 2016 Deals Resulting in NIAGEN Products Being Available in Retail
2016 Deals Resulting in NIAGEN Products Being Available in Thousands of Retail Locations Shelly ulfon Grove, Inc. stores nationwide, as part of its innovation partnership with the world's in GNC stores. BPI Sports featuring Gey in Costco, Walmart, Wielereens, Torget, Meier, Kroger, Publix, hold, Ult
Slide 24: Exclusive Development Agreement with P&G
Exclusive Development Agreement with P&G hromaDex an Cc NIAGEN® id P. for use in speciic consumer ee fields for both existing and n 1ent positions our Impertent Deal Terms: Team Undisclosed pt Payment innovative new ingredient to be + Development Coste Paid by P&G included in a number of P&G + Miles
Slide 25: Patent Portfolio Controlling the NAD+ Precursor Space
Patent Portfolio Controlling the NAD+ Precursor Space ‘gatekeeper + us8106184: Us 8114626: Manufacture of NR via recombinant microorganisms us 8197807: NR for increasing NAD+ biosynthesis us 8383086: US 7776326: @ eee i Dartmouth RoE Scrromadex b
Slide 26: Current Portfolio of Proprietary Ingredients
Current Portfolio of Proprietary Ingredients / NIAGEN. riboside (NR), a highly effective NAD+ booster. +P pleréPure gers PURENERGY ae IMMULINA WN ieee eee ‘enhance the immune response. ProC3G. , _ Saerawee sugar support, heart health and eye health. Scrromadex bh
Slide 27: Ingredient Development Pipeline
Ingredient Development Pipeline Product Potential Benefits Projected Launch Pipeline Product 1 Purple Corn Anthocyanin (Suntava) 2016 ipelir NAD Metabolite 1 2016 NAD Metabolite 2 2016 Weight Loss 2016 NAD Metabolite 3 2017 Pipeline Product i iit 2017 ChromaDex b
Slide 28: ChromaDex Following the Model of Others
ChisMansé: is Following the Model e Other fo! marreKo” ChromaDex Market Cop* ~$187M Market Cop* ~$130M Market Cap* ~$117M Market Cap* ~$1.868 Approximate Market Cap* as of 03/10/15
Slide 29: Scientific Advisory Board
pA Ka A aDex. SCIENTIFIC ADVISORY BOARD 2 Be Bevdeher ‘Germon + The other SAB members are: ChromaDex. é
Slide 30: ChromaDex Highlights
ChromaDex Highlights (NIAGEN. ) plerPure se eke ne ne inanuinas 22% sequentially ProC3G. \ Gonsnagizenae the type of opportunity eerpenciny AB em Gare eee Greer NAD: of the treatment of ce SIT eS tinamide riboside. A new vit = peer ieces of the care cfeaing a perfeao IA h, Jt, CEO and Co-Founder of
Slide 31: Appendix: Additional Company Information
> ChromaDex. Appendix Additional Company Information
Slide 32: ChromaDex at a Glance
ChromaDex at a Glance egments of our Legacy Business eee Natural product esrebileake Spherix consulting fine chemicals \emisiry-based services ices NIAGEN. ; J y ws plerePure 4B punchy <> = Largest ccna + Analytical testing + Aglobal leader in tal products for ee scientific e regulatory IMMULINA" 8
Slide 33: ChromaDex's Unique First-mover Advantage
ChromaDex's Unique i First-mo dvant i ‘atented Boctatany ingredient Technologies Over 1500 Indsey Customs Over 250 University & Research Institute customers Dartmouth Gargur PEPSICO Gans nian @ coterie Stanford USDA ae University ESTEE LAUDER ChromaDex b
Slide 34: ChromaDex Discovery
ChromaDex Disc quire ry Ingredient iecover novel eorlystoge ingrecient tect Exclusively leense these Conmeritic ia mu nologies, ingredient teehaalogies ‘elgg ni leverosingineigence cod ouzciated IP ‘gained from activities of In nt rot Sptyeton Snotpne in = Sink cope = toy eye NIAGEN. pleréPuré -ugeX
Slide 35: pTeroPure IP-backed, Clinically-Studied Branded Ingredient
pTeroPure® i P-backed, Clinically-Studied Branded Doociibone Overview The only form of pterostibene with GRASI status + Supported by clinical studies ond IP Scrromapex bh Q eal
Slide 36: pTeroPure Clinical Study Results on Blood Pressure
pTeroPur hich Showed Results for its Ability to Lower Blood Pre: No serious adverse events of this study highlight thot pees ei Riche, PharmD, Cardiometabolic Cl promising ingredient in the area of cardior Dar tor at the University of Mississippi School of Pharmacy Chromadex b © i pler®Pure
Slide 37: Uses of pTeroPure in Skin Protection Market
Uses of pTeroPure® in S| d Protection Market: Topical Pterostilbene Study + On April 3%, 2015 i associated skin damage Based on these re the researchers proposed the use of pterostilbene for the prevention of skin carcinogenesis induced by solar reditior the topical applications of pterostilbene. Au
Slide 38: PURENERGY Patent Protected Caffeine Ingredient
PURENERGY® is ChromaDex'’s Patent Protected and Clinically Studied Caffeine Ingredient we Z plemPUre + Coffeme = RURENERGY WS Overview ct least 6 hours!. a “erosh! high-suger products. : P PP P p Where con Weight I sndurance training nd concentration © chromadex
Slide 39: PURENERGY Clinical Results - 2013
PURENERGY® Clinical Results - 2013 Results of Study lerGy® is extended signif ENERGY” 7, there was 51% more caffeine from PURENERGY” compared to ordinary cafeine lone. a ie subjects taking PURENERGY” Sobieas inesing ordinry caffeine did not oo e hour, sblecetoking PURENERGY ingesting ‘ordinary caffe
Slide 40: Statements of Operations (Three Months)
Statements of Operations! For he Three Month Periods Endod Oct 5, 2015 and Sop. 27, Sales, et § gzeace s 4xers0 Cont ofeses Sengere * 2516764 Gross prot zapyen 1522095 petting ‘Sole an marking snare sta¢a2 Genera and acminetatve qrsieze 1651716 ‘Operating expenses 204800 2.70380 Operating toss sna e
Slide 41: Statements of Operations (Nine Months)
Statements of Operations! For the Nine Month Periods Ended Oct 3, 215 nd Sep. 27,2014 2015 Sop 27,2016 Sates. et 'S ‘7649660 s 11070002 Contof sales sorear "7503289 Gross 3906.70 pert Sols and a7, 1554 Goiessr — Gaseor tose om vesinetn ate ¥ 21548 Operating expences Tasos sar vpene surement nto Oper
Slide 42: Balance Sheets
Balance Sheets! ‘con green sam 709 Trasercoatos Sasa * Ser Seem Sate Taser a er usin i cera 5S ssigss 5 so0m0 onpyaie ns cent manta, tone * tars Ceptalere ceignons scone antes ‘ona "ais ‘Sekeesee Seoast___‘srscs ‘sat is2T asta pacn tot soma gata Remnant et ioomrey — Gaeon Tolltbilos nd echoes oguty
Slide 43: Statements of Cash Flows
Statements of Cash Flows! Forth Nine Month Prlods Ended Oct. 3,2016and Sap 27,204 ct 32,2015, te ‘cach Fows From Operatg Acbites less 5 (134442) s (as608t0) aament to 4s tonateash ‘edn operat ans ; 268 ineperaing assets an tabites: (sre 485 Neteaah usedin operating activities (257582 ‘Gash Flows Fro
Slide 44: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation! sof Charges soled wih ners, Ta Deprecaon, Console Suman of Operon, Adjusted STOR xling tre, Tx Oaprsaton metzaton sod Sharad Contato Sutera of Operations sour) Amotzaton sn SarbsuedConpenson Epes robs Compesaion Won GAAP Presta) Forte 2 oth Periods End Oe 2, 25
Slide 45: Contact Information
ChromaDex. Contact Information ‘ChromaDex Corporation Andrew Johnson Director of Investor Relations Phone: +1-949-419-0288 cendrewi@chromadex.com